GlaxoSmithKline (GSK) And Bentley Pharmaceuticals (BNT) Mutually Agree To Dismiss All Claims Of Paroxetine Patent Infringement In Spain
10/19/2005 5:10:20 PM
EXETER, N.H.--(BUSINESS WIRE)--May 11, 2005--Bentley Pharmaceuticals, Inc. (NYSE: BNT), a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe, today announced that a Spanish court terminated judicial proceedings among Bentley's Spanish subsidiary, Laboratorios Belmac S.A. and its subsidiaries, and SmithKline Beecham PLC, SmithKline Beecham, S.A. and GlaxoSmithKline S.A. (collectively "Glaxo"), upon agreement among the parties to dismiss, without recourse, all paroxetine-related patent infringement claims in their litigation in Spain.
This settlement arises out of a suit brought by Glaxo against Bentley in October 2003 alleging that Bentley had violated Glaxo's patents in the production of paroxetine products after Bentley launched its paroxetine product line in May 2003. The complaint, which was brought in Madrid against Bentley's Spanish subsidiaries, followed a preliminary injunction that Glaxo sought against Bentley in 2003 that was dismissed in June 2003. This 2005 agreement also dismissed Bentley's counterclaim requesting that the court declare Glaxo's asserted patent invalid.